Dr. Steven Baker

Division of Physical Medicine and Rehabilitation

Steven Baker


Associate Professor, Division of Physical Medicine and Rehabilitation, Department of Medicine

Research Director, Division of Physical Medicine and Rehabilitation

Hamilton Hospitals Assessment Center Endowed Professorship in Neuromuscular Diseases




Education and Professional Standing

  • BA, Wilfrid Laurier University, 1993
  • BEd, University Western Ontario, 1994
  • MSc, University of Waterloo, 1996
  • MD, McMaster University, 2000
  • FRCP(C), McMaster University, 2005

Professional Organizations

  • American Academy of Neurology (AAN)
    Junior Member since 2000
  • American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
    Associate Member since 2005
  • Canadian Society of Clinical Neurophysiologists (CSCN)
    Active Member since 2005
  • Royal College of Physicians & Surgeons of Canada
    Active Member since 2005
  • College of Physicians & Surgeons of Ontario
    Active Member since 2005

Areas of Interest

I have interests in the pathophysiologic mechanisms underlying statin-associated neuromuscular toxicity as well as acquired, i.e., chemotherapy-related neuropathy, and inherited, i.e., CMT, disorders of the peripheral nervous system. Seeking novel neuroprotective treatment strategies will be a major focus of my work.

I believe in-hospital education for both undergraduate and post-graduate medical trainees should occur in an unthreatening and collegial environment. In this setting, learners can be tested through critical reasoning and problem-solving exercises with the combined results of increased self-appraisal and self-esteem. I believe Physical Medicine and Rehabilitation residents, due to their diverse training experiences, need a system of continuous review to facilitate retention of knowledge acquired on previous rotations. This must occur through improved academic rounds and possibly web-based learning modules and/or mandatory case-centered questioning and reviews.

I am presently heading the peripheral nerve service at McMaster’s new neuromuscular/neurometabolic disease clinic under the directorship of Dr. Mark A. Tarnopolsky. I also have interest in toxic myopathies including statin related neuromuscular side-effects.

Selected Publications

Book Chapters & Review Articles:

  1. Baker, S.K. Toxic Myopathies. Neuromuscular Disorders for Neurology in Practice. Rabi N. Tawil and Shannon Venance (eds.). Neuromuscular Disorders (Wiley-Blackwell) August 2011
  2. Antons, K., Williams, C., Baker, S.K., & Phillips, P.S. (2006). Clinical perspectives of statin-induced rhabdomyolysis. Am. J. Med. 119(5):400-9.
  3. Baker, S.K. (2005) Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle & Nerve, 31(5): 572-580.
  4. Baker, S.K. & Tarnoplosky, M.A. (2003). Targeting cellular energy production in neurological disease. Expert Opinion on Investigational Drugs, 12(10): 1655-1679.
  5. Baker, S.K. & Tarnopolsky, M.A. (2001). Statin myopathies: pathophysiologic and clinical perspectives. Clin. Invest. Med., 24(5): 258-272.
Journal Articles:
  1. Mancini, GBJ, Baker, SK, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor Y. Diagnosis, Prevention and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology. Accepted for publication January 5, 2016. Doi: 10.1016/j.cjca.2016.01.003
  2. Varley TL, Bourque PR, Baker SK. Phenotypic Variability in French-Canadian Kindred with Novel Combination of Heterozygous SH3TC2 Mutations. Muscle & Nerve, 2015 Mar 3. doi: 10.1002/mus.24640
  3. Baker SK , Chow  BM,  Vernino SA,. Transient Neonatal Autoimmune Autonomic Ganglionopathy. Neurology  Neuroimmunology & Neuroinflammation. 2014 Sep 18;1(3):e35. doi: 10.1212/NXI
  4. Lavigne A, Baker SK. CMT1A and T2DM versus CMT1A alone: A retrospective comparison of nerve conduction values and terminal latency index. J Neuro Clsci. August 2014, Volume 1, Issue 1: 005
  5. Wu Y, Lach B, Provias J, Tarnopolsky MA, Baker SK. Statin-associated autoimmune myopathies: a pathophysiologic spectrum. Canadian journal of Neurological Sciences,  2014 Sep;41(5):638-47. doi: 10.1017/cjn.2014.22.
  6. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S58-71. doi: 10.1016/j.jacl.2014.03.004.
  7. Mancini, GBJ, Baker, S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J. Consensus Overview of the Diagnosis, Prevention and management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. Can J Cardiol. 2013 Dec;29(12):1553-68. doi: 10.1016/j.cjca.2013.09.023. Epub 2013 Sep 29.
  8. Isackson, P., Ochs-Balcom, HM, Ma C, Baker SK, et al. (2011) Association of a common variant in the human eyes shut ortholog, EYS, with statin-induced Myopathy: evidence for additional functions of EYS.  Muscle & Nerve October 2011, DOI 10.1002/mus.22115
  9. Mancini, GBJ, Baker, S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J. Consensus Overview of the Diagnosis, Prevention and management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group. The Canadian Journal of Cardiology.  2011, doi.1016/j.cja.2011.05.007
  10. Hooper DR,  Lawson W, Smith L, Baker SK. Sonographic Features in Hereditary Neuropathy with liability to Pressure Palsies. Muscle & Nerve. 2011 Dec;44(6):862-7. doi: 10.1002/mus.22199
  11. MacNeil L, Baker, SK, Stevic I, and Tarnopolsky MA. R-00689-2009R1 - 17β-estradiol attenuates exercise-induced neutrophil infiltration in men. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology. 2011 Jun;300(6):R1443-51. Epub 2011 Mar 2.
  12. Gomez Vargas, A, Baker, SK. Molecular Diagnosis of Myopathies. Rheumatic Disease Clinics of NA Volume 37, Issue 2, May 2011 doi;10.1016/j.rdc.2011.01.009
  13. Burd NA, West D, Staples AW, Atherton P, Baker SK, Baker JM, Parise G, Rennie M, Moore D, Holwerda A. Low-load high volume resistance exercise stimulates muscle protein synthesis more than high-load low volume resistance exercise in young men. PLos ONE 2010 Aug 9;5(8):e12033
  14. Holbrook AM, Wright M, Sung M, Ribic C, Baker SK. Statin-Associated Rhabdomyolysis: Is there a dose-response relationship?  The Canadian Journal of Cardiology 2011;27(2):146-51; Publication award “ 2012 CCS Robert E. Beamish Award, Canadian Cardiovascular Society”
  15. MacNeil LG, Melov S, Hubbard AE, Baker SK, Tarnopolsky MA (2010) Eccentric Exercise Activates Novel Transcriptional Regulation of Hypertrophic Signaling Pathways Not Affected by Hormone Changes. PLoS ONE 2010 May 18;5(5): e10695.
  16. Baker, SK, Lipson, D.  Vincristine-Induced Peripheral Neuropathy in a Neonate with Congenital Acute Lymphoblastic Leukemia. J pediatr Hematol Oncol.  2010 April;32(3):e114-7.
  17. Miller, M, Rosenson, R, Baker, S. Muscle injury associated with lipid lowering drugs. In: UpToDate, Basow, DS(Ed), UpToDate, Waltham, Ma, 2009
  18. Ewart, T. Tarnopolsky, M, Baker, SK., Raha, S., Wong, Y., Ciebiera, K., "Multiplex infectious disease microarrays: STAT serology on a drop of blood" in Photodynamic Therapy: Back to the Future, Proceedings of SPIE Vol. 7380 (SPIE, Bellingham, WA 2009) 73806E
  19. Myers KA, Baker S.K.  Late-onset Seropositive Isaac’s syndrome after Guillaine-Barré Syndrome. Neuromuscul Disord. 2009 Apr;19 (4):288-90.
  20. Baker, SK. (2009) Characterization of a novel C8 phasic muscle stretch reflex. Muscle and Nerve.  2009 Oct;40(4):529-34.
  21. Baker, S.K, Morrillo, C, Vernino, S.  Autoimmune Autonomic Ganglionopathy with Late-onset Encephalopathy. Auton Neurosci.. (2009) Mar 12;146(1-2):29-32.
Journal/Conference Abstracts:
  1. Baker SK. Seropositive PERM Associated with Leucocytoclastic Vasculitis. CNSF Congress 2015.
  2. Baker SK,/Novel VCP Mutation Associated With CMT2 Phenotype. CNSF Congress 2015.
  3. Varley T, Bourque P, Baker SK. Phenotypic Variability in French-Canadian Kindred with Novel combination of Heterozygous SH3TC2 Mutations. American Academy of Neurology 65th Annual Meeting, 2013
  4. Hornemann T, Bode H, Baker SK. Exogenous L-Alanine Increases Deoxysphingolipids in Patients harboring R151L Mutation in SPTLC, AANEM 59th Annual meeting in 2012
  5. Baker SK. Quantitative Strength Testing in CMT Patients exposed to Lipid-Lowering Therapy, AANEM 59th Annual meeting in 2012
  6. Baker SK. Novel MFN2 Mutation Causing Compound Heterozygous Autosomal Recessive CMT2A, AANEM 59th Annual meeting in 2012
  7. Baker SK. Axonal Phenotype in Genetically confirmed CMT1A, Carrell-Krusen Symposium, Dallas Texas, February 2012
  8. Jarinova O, Warman J, Goldsmith C, Carson N, McCready E, Yoon G, Baker S, Innes M, Boycott KM. Development of high throughput targeted resequencing array for the diagnosis of hereditary neuropathies. Presented at meeting titled “Human Mutation”, May 2011
  9. Baker SK. Novel Autosomal Dominant FIG4 Mutation Causing CMT1Phenotype. Carrell-Krusen Symposium, Dallas Texas, February 2011
  10. Baker SK. Transient Neonatal Autoimmune Autonomic Ganglionopathy. Carrell-Krusen Symposium, Dallas Texas, February 2011
  11. Staples AW, Sherriffs SS, Burd NA, West DWD, Moore DR, Tang JE, MacDonald MJ, Baker SK, and Phillips SM. Muscle protein synthesis is not augmented by protein-carbohydrate co-ingestion at rest or following resistance exercise.  Med Sci Sports Exec. 41(5): 150, May 2009